<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Susan M. Wolf</style></author><author><style face="normal" font="default" size="100%">Gupta, Rishi</style></author><author><style face="normal" font="default" size="100%">Kohlhepp, Peter</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gene Therapy Oversight: Lessons for Nanobiotechnology</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Law, Medicine &amp; Ethics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BIOTECHNOLOGY</style></keyword><keyword><style  face="normal" font="default" size="100%">GENE therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">GENETIC transformation</style></keyword><keyword><style  face="normal" font="default" size="100%">MEDICINE -- Research</style></keyword><keyword><style  face="normal" font="default" size="100%">NANOTECHNOLOGY</style></keyword><keyword><style  face="normal" font="default" size="100%">RESEARCH</style></keyword><keyword><style  face="normal" font="default" size="100%">TECHNOLOGICAL innovations</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Winter2009</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">37</style></volume><pages><style face="normal" font="default" size="100%">659-684</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The authors discuss how the oversight of human gene transfer research presents an important model with potential application to oversight of nanobiology research on human participants.  This article traces the evolution of the dual oversight system currently in place for gene therapy; describes how the system is already addressing nanobiotechnology in gene transfer: evaluates gene therapy oversight based on public opinion, the literature, and preliminary expert elicitation; and offers lessons of the gene therapy oversight experience for oversight of nanobiotechnology. </style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><accession-num><style face="normal" font="default" size="100%">46823895</style></accession-num><notes><style face="normal" font="default" size="100%">Wolf, Susan M. 1 Gupta, Rishi 2 Kohlhepp, Peter 3; Affiliation: 1: McKnight Presidential Professor of Law, Medicine &amp; Public Policy; Faegre &amp; Benson Professor of Law; Professor of Medicine; and Faculty Member in the Center for Bioethics at the University of Minnesota. 2: Holds an M.S. in Applied Physics from the University of Texas at Dallas and a J.D. from the University of Minnesota Law School. He is currently an Associate at Fish and Richardson PC. in Dallas, Texas. 3: Received his J.D. from the University of Minnesota Law School in May 2009. He is currently an Associate at Carlson, Caspers, Vandenburgh and Lindquist in Minneapolis.; Source Info: Winter2009, Vol. 37 Issue 4, p659; Subject Term: GENE therapy; Subject Term: BIOTECHNOLOGY; Subject Term: NANOTECHNOLOGY; Subject Term: TECHNOLOGICAL innovations; Subject Term: GENETIC transformation; Subject Term: RESEARCH; Subject Term: MEDICINE -- Research; NAICS/Industry Codes: 541712 Reseach and Development in the Physical, Engineering, and Life Sciences (except Biotechnology); Number of Pages: 26p; Illustrations: 3 Charts; Document Type: Article</style></notes></record></records></xml>